KPV vs TB-500
A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
KPV
KPV is a C-terminal tripeptide fragment (Lys-Pro-Val) of alpha-melanocyte stimulating hormone (α-MSH). Despite its small size — just three amino acids — it retains the anti-inflammatory core activity of its parent molecule without the melanogenic effects. It is one of the most researched peptides for gut inflammation, IBD, and intestinal permeability, with the ability to act locally in the gut when administered orally.
Full profileTB-500
TB-500 is a synthetic fragment of Thymosin Beta-4, an endogenous protein involved in cell migration, tissue repair, and inflammation regulation. It has shown significant healing properties in preclinical models across muscle, tendon, ligament, and cardiac tissue.
Full profile| KPV | TB-500 | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Also known as | Lys-Pro-Val, Alpha-MSH C-terminal tripeptide | Thymosin Beta-4, Tβ4, TB500 |
| Evidence | Research-stage | Preclinical only |
| Dosing range | 250mcg–1000mcg mcg, Once or twice daily | 2mg–10mg mg, twice weekly (loading), weekly (maintenance) |
| Administration | Subcutaneous injection, Oral (encapsulated — for gut-specific delivery), Intranasal | Subcutaneous injection, Intramuscular injection |
| Key side effects | Generally well-tolerated, Mild injection site irritation, Transient headache (uncommon), No melanogenic effects (does not cause tanning unlike full α-MSH) | Head rush / lightheadedness (transient), Lethargy at higher doses, Injection site discomfort, Nausea (rare) |
| Cited sources | 3 references | 2 references |
Key differences
- Evidence level differs: KPV is research-stage, while TB-500 is preclinical only.
- Administration: KPV — Subcutaneous injection, Oral (encapsulated — for gut-specific delivery), Intranasal; TB-500 — Subcutaneous injection, Intramuscular injection.
- Dosing units differ: KPV is dosed in mcg, TB-500 in mg — they operate at different scales.
- Frequency: KPV is typically Once or twice daily; TB-500 is twice weekly (loading), weekly (maintenance).
- Research depth: this profile cites 3 sources for KPV vs 2 for TB-500.
How each works
KPV
KPV exerts anti-inflammatory effects through melanocortin receptor-independent mechanisms as well as via MC1R and MC3R activation. It downregulates NF-κB, inhibits pro-inflammatory cytokines (TNF-α, IL-1β, IL-8), and reduces neutrophil infiltration in colonic tissue. Uniquely for a peptide, KPV is acid-stable enough to survive gastric transit and reach the intestinal mucosa intact, making oral delivery viable for gut-targeted applications — a significant advantage over most injectable-only peptides.
TB-500
TB-500 promotes healing by upregulating actin, which drives cell migration to injury sites. Animal studies show accelerated repair of muscle tears, tendon injuries, and corneal wounds. It also demonstrates anti-inflammatory properties and has been studied for cardiac tissue repair following ischemic injury.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.